Search results
This Pharma Stock Is Poised to Keep Outperforming the S&P 500 | The Motley Fool
The Motley Fool· 4 days agoAstraZeneca (AZN 1.23%), recognized as the world's sixth-largest pharmaceutical entity by market...
AstraZeneca started at buy at Goldman, which rates GSK a neutral
Market Watch· 4 days agoGoldman Sachs started coverage of AstraZeneca at buy as it rated rival pharmaceutical company GSK a...
AstraZeneca CEO Has No Plans to Retire as He Seeks to Nearly Double Sales by 2030
The Wall Street Journal· 3 days agolongest-serving chief executive, Pascal Soriot, has no plans to step down for now as the company...
Pharma giant GSK plunges 9% after U.S. court allows scientific testimony in Zantac lawsuits
CNBC· 8 hours agoCompany logo of pharmaceutical company GlaxoSmithKline is seen at their Stevenage facility, Britain...
Chasing Merck, AstraZeneca's PCSK9 inhibitor lowers cholesterol in phase 1 test
FierceBiotech· 5 days agoAstraZeneca’s small molecule lowered levels of “bad” cholesterol by more than half in patients who...
Parallel Advisors LLC Sells 169 Shares of AstraZeneca PLC (NASDAQ:AZN)
ETF DAILY NEWS· 4 days agoParallel Advisors LLC reduced its stake in AstraZeneca PLC (NASDAQ:AZN – Free Report) by 1.2% during the fourth quarter, according to the company in its most recent 13F filing ...
Commerce Bank Trims Holdings in AstraZeneca PLC (NASDAQ:AZN)
ETF DAILY NEWS· 6 days agoCommerce Bank lessened its stake in AstraZeneca PLC (NASDAQ:AZN – Free Report) by 10.6% in the 4th quarter, according to the company in its most recent filing with the Securities ...
JPMorgan bullish on AstraZeneca stock, highlights AZD0780's sales By Investing.com
Investing.com· 6 days agoOn Tuesday, JPMorgan (NYSE:JPM) maintained its positive stance on AstraZeneca (NASDAQ:AZN:LN)...
AstraZeneca’s (AZN) “Buy” Rating Reaffirmed at Citigroup
ETF DAILY NEWS· 6 days agoCitigroup reissued their buy rating on shares of AstraZeneca (LON:AZN – Free Report) in a report published on Tuesday, Marketbeat reports. Several other analysts have also ...
Amgen Secures FDA Nod For Rare-Disease Treatment Biosimilar Based On AstraZeneca's Drug
Benzinga via Yahoo Finance· 5 days agoTuesday, the FDA approved Amgen Inc (NASDAQ:AMGN) Bkemv (eculizumab-aeeb) as the first...